Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)

Daniel J. Sheward^{1,2}, Changil Kim¹, Roy A. Ehling³, Alec Pankow¹, Xaquín Castro Dopico¹, Darren Martin², Sai Reddy³, Joakim Dillner⁴, Gunilla B. Karlsson Hedestam¹, Jan Albert^{1,5}, Ben Murrell¹

¹ Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

² Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa

³ Department of Biosystems Science and Engineering, ETH Zürich

⁴ Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.

⁵ Dept of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden

Abstract

The recently-emerged SARS-CoV-2 B.1.1.529 variant (Omicron) is spreading rapidly in many countries, with a spike that is highly diverged from the pandemic founder, raising fears that it may evade neutralizing antibody responses. We cloned the Omicron spike from a diagnostic sample which allowed us to rapidly establish an Omicron pseudotyped virus neutralization assay, sharing initial neutralization results only 13 days after the variant was first reported to the WHO, 8 days after receiving the sample.

Here we show that Omicron is substantially resistant to neutralization by several monoclonal antibodies that form part of clinical cocktails. Further, we find neutralizing antibody responses in pooled reference sera sampled shortly after infection or vaccination are substantially less potent against Omicron, with neutralizing antibody titers reduced by up to 45 fold compared to those for the pandemic founder. Similarly, in a cohort of convalescent sera prior to vaccination, neutralization of Omicron was low to undetectable. However, in recent samples from two cohorts from Stockholm, Sweden, antibody responses capable of cross-neutralizing Omicron were prevalent. Sera from infected-then-vaccinated healthcare workers exhibited robust cross-neutralization of Omicron, with an average potency reduction of only 5-fold relative to the pandemic founder variant, and some donors showing no loss at all. A similar pattern was observed in randomly sampled recent blood donors, with an average 7-fold loss of potency. Both cohorts showed substantial between-donor heterogeneity in their ability to neutralize Omicron. Together, these data highlight the extensive but incomplete evasion of neutralizing antibody responses by the Omicron variant, and suggest that increasing the magnitude of neutralizing antibody responses by boosting with unmodified vaccines may suffice to raise titers to levels that are protective.

Introduction

A new SARS-CoV-2 variant, B.1.1.529 (designated “Omicron” by the WHO) is rapidly replacing the highly transmissible Delta variant (B.1.617.2) in many countries. Relative to the pandemic founder, the archetypical Omicron variant harbors two deletions, one insertion, and 30 amino acid differences in the viral spike, including many known or predicted to confer resistance to neutralizing antibodies¹. However, their combined effect, and the phenotypic effects of a number

of novel Omicron mutations are unknown. Such a substantial antigenic shift may undermine protection afforded by currently licensed vaccines, and monoclonal antibodies used in the clinic. We therefore characterized, using a pseudotyped virus assay, the sensitivity of Omicron to neutralization by relevant monoclonal antibodies, pooled serum from vaccinees, serum samples from infected and infected-then-vaccinated healthcare workers, as well as a random sample of recent seropositive blood donors.

Results

An Omicron variant spike was molecularly cloned from an anonymized diagnostic sample, suspected to contain B.1.1.529 due to S-gene target failure. A region of spike from before-the-first to after-the-last mutation in Omicron (codons corresponding to amino acid positions 43 to 1000) was PCR amplified from cDNA, subcloned into a spike expression vector, and confirmed by sequencing to encode the Omicron consensus sequence (Supp. Table 1). Using this molecular spike clone, we generated pseudotyped lentiviral particles, and assessed the relative sensitivity of the Omicron variant to neutralization.

The First WHO International Standard immunoglobulin (20/136) - pooled from convalescent patients in 2020 - showed a ± 40 -fold reduction in the neutralization of Omicron compared to the pandemic founder ('wild-type', WT) (IC_{50} from 0.6 IU/ml to 23.4 IU/ml) (Fig. 1A), indicating substantial resistance to antibodies elicited by ancestral SARS-CoV-2 infection, in line with the significant neutralization resistance observed for Omicron in parallel live virus assays².

Next, to evaluate the likely impact of Omicron on the efficacy of vaccine-elicited antibodies, we assessed the neutralization of Omicron by pooled serum standards from BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna) and Ad26.COV2.S (Johnson&Johnson) vaccine recipients. We found that neutralization of Omicron was substantially reduced, from 7 to 45 fold, across the vaccine standard serum pools (Fig. 1B-D).

Figure 1. Significant resistance of SARS-CoV-2 B.1.1.529 (Omicron) to antibody neutralization by reference reagents A. Neutralization of the Omicron variant by the First WHO International Standard Immunoglobulin from convalescent individuals. **C-F.** Neutralization of the B.1.1.529 (Omicron) variant compared to wild-type and B.1.617.2 (Delta) by pooled sera standards from vaccinees receiving **(B)** mRNA-1273 (Moderna), **(C)** BNT162b2 (Pfizer/BioNTech), or **(D)** Ad26.Cov2.S (Johnson & Johnson). Error bars depict mean $\pm$ SD. The WHO International Standard Immunoglobulin was assayed only once per variant, due to reagent limitations.

While neutralization in serum sampled shortly following vaccination provides critical information about the antibody responses elicited and boosted by vaccines, immunity at the population level and ‘real-world’ vaccine protection incorporates not just vaccination, but a variety of previous and subsequent exposures, as well as the waning³⁻⁵ of the responses to these. Therefore, to provide a snapshot of status of immunity at the population level, prior to the introduction of Omicron, we assessed neutralization by sera from two cohorts from Stockholm, Sweden: (i) 17 randomly selected seropositive recent blood donors (anonymized and therefore unknown exposure and vaccination status) and (ii) 17 recently-sampled hospital workers (HW) who were infected in May 2020, with varied subsequent vaccination histories (Supp. Table 2).

Neutralizing ID₅₀ titers for the blood donors were $\pm$ 7-fold lower against Omicron compared to WT (Fig 2B). However, the reduction in neutralizing activity was heterogeneous, with some sera nearly 25-fold less potent and others experiencing no significant loss, indicating the presence of cross-neutralizing antibodies in a subset of donors. Similarly, sera from hospital workers were, on average, $\pm$ 5-fold less potent against Omicron and also exhibited considerable inter-individual variation (Fig. 2B).

Importantly, historical samples taken from the HW cohort after confirmed SARS-CoV-2 infection, but prior to vaccination (convalescent), showed a near-complete loss of neutralizing activity

against Omicron (Fig. 2C). However, for seven hospital workers that received two doses of BNT162b2 after infection, robust cross-neutralization of Omicron was evident in a number of individuals (Fig. 2D), highlighting the improvement in the neutralisation of variants afforded by vaccination in previously infected individuals.

Figure 2: Characterization of the relative neutralization resistance of Omicron. A-B. Paired WT and Omicron pseudovirus neutralization titers for the Recent Blood Donor (BD; N=17) and Hospital Worker (HW; N=17) cohorts against the pandemic founder (WT) and B.1.1.529 (Omicron). C. Samples taken from the HWs approximately one (▲) or four (▼) months after infection, but prior to vaccination (convalescent) show a substantial reduction in the ability to neutralize Omicron, with all ID₅₀s falling below the limit of detection (20). D. For seven HW that reported receiving two doses of BNT162b2 subsequent to infection, cross-neutralization of Omicron was evident.

Table 1. Failure of several monoclonal antibodies included in therapeutic cocktails to neutralize the Omicron variant.

mAb	D614G IC ₅₀ (μg/ml)	Omicron IC ₅₀ (μg/ml)	Fold Loss
REGN-10933 ⁶	0.009	>10	>1100
REGN-10987 ⁶	0.008	>10	>1200
LY-CoV555 ⁷	0.007	>10	>1400
LY-CoV16 ⁸	0.04	>10	>270
S309 ⁹	0.1	0.2	2

Monoclonal antibodies represent important treatment and prophylactic options for certain categories of patients, and can significantly reduce morbidity in those otherwise at risk for severe COVID-19¹⁰. We therefore evaluated the sensitivity of the Omicron variant to neutralization by several monoclonal antibodies currently included in therapeutic cocktails used in the clinic. REGN10933, REGN10987, Ly-CoV016 and Ly-CoV555, all failed to neutralize Omicron up to the highest concentration tested (10 μg/ml) despite potently neutralizing the ancestral B.1 (D614G) spike (Table 1). However, the parent of Sotrovimab, S309, maintained much of its activity, experiencing only a 2-fold loss in potency against Omicron (Table 1).

Discussion

Neutralizing antibodies are a mechanistic correlate of SARS-CoV-2 vaccine protection^{11,12}. While other arms of the immune system contribute to protection from severe disease, the significant reduction in neutralization sensitivity that we document here will likely translate into an erosion of vaccine-mediated protection. This is supported by the recent, rapid spread of Omicron in countries with high vaccine coverage¹³, as well as preliminary reports of multiple breakthrough infections¹⁴.

We show that there is a precipitous drop in neutralization potency against Omicron for serum pools from convalescent donors and recently vaccinated individuals, as well as from individual convalescent donors sampled soon after initial infection. However, sera from a high-risk cohort¹⁵ of infected-then-vaccinated health care workers exhibit substantial cross-neutralization of Omicron, which correlates with their ability to cross-neutralize other variants. This suggests that responses to SARS-CoV-2 spike broaden with increasing antigenic exposure. This has been characterized against other variants in the context of both prior infections¹⁶ and three-dose vaccinations¹⁷.

Interestingly, responses in a cohort of random recently-sampled Stockholm seropositive blood donors also exhibited substantial cross-neutralization of Omicron. On average, the fold loss against Omicron was only slightly greater than that of the previously infected hospital worker cohort. Such cross neutralization in a “real world” cohort would not have been predicted from the responses observed at the peak post-vaccination². As most individuals in Sweden have only received two vaccine doses, this breadth may then be explained by the frequency of exposures prior to, or following, vaccination in Stockholm, Sweden. Alternatively, there may be systematic differences in cross neutralization for samples taken immediately after a second immunization compared to those sampled later. Indeed, affinity maturation of antibody lineages over the course of months after SARS-CoV-2 infection enabled the cross-neutralization of variants of concern, and heterologous sarbecoviruses¹⁸.

From a global health perspective, the dramatic loss of neutralization against Omicron for previously-infected but unvaccinated individuals has implications for whether such individuals can be considered immune. Further, the cross-neutralizing antibody responses in the infected-then-vaccinated hospital worker cohort indicate significant value in vaccinating the previously-infected.

Given the complete resistance of Omicron to several monoclonal antibodies currently included in cocktails used in the clinic, treatment options should be informed by rapid SARS-CoV-2 genotyping in regions where Omicron and Delta (or other variants) are both circulating. This also argues for the rapid diversification of our clinical monoclonal antibody portfolio, to hedge against unpredictable potency losses for future variants. It also highlights the need to rapidly screen variants for their sensitivity to clinical therapeutics.

Methodologically, the current standard practice for generating pseudovirus spike expression plasmids for novel variants relies on site-directed mutagenesis when only a small number of

mutations differ from an existing plasmid construct, or gene synthesis to generate entire spike genes. Exceptional urgency is demanded by the emergence of a rapidly-spreading novel variant with a large number of spike mutations. Molecular cloning from a diagnostic sample allowed us to circumvent gene synthesis delays, and share pseudovirus neutralization data just eight days after receipt of the suspected Omicron diagnostic samples, and 13 days after the variant was first reported to the WHO¹⁹. One risk associated with this approach is that, if the expression of a non-codon optimized spike is too low, pseudovirus entry into target cells may be too inefficient to accurately quantify neutralization. For this reason, our cloning strategy retained as much of the codon-optimized backbone as possible, especially in the C-terminal region of the spike, which is not mutated in Omicron. It is not clear whether such a strategy would universally succeed with all variants, so a dual approach that attempts gene synthesis and direct cloning (when samples are available) would mitigate this risk.

Ultimately, long-term protection against SARS-CoV-2, including antigenic variants that will arise, may require updated vaccines or vaccines that elicit more broadly cross-neutralizing antibodies. Until such vaccines are available, our data from two different cohorts suggests that the loss of neutralization against Omicron is incomplete. It has previously been shown, with other variants, that a third dose with unmodified vaccines may have a broadening effect¹⁷. But even without such a booster broadening effect, in many donors the magnitude of loss in neutralization we observe against Omicron argues that antibody titers may be boostable into a protective range with currently licensed vaccines.

Acknowledgements

We acknowledge the G2P-UK National Virology consortium funded by MRC/UKRI (grant ref: MR/W005611/1) and the Barclay Lab at Imperial College for providing B.1, B.1.351, B.1.617.2, and B.1.621 spike-encoding plasmids. We acknowledge Penny Moore and the NICD (South Africa) for providing a B.1.351 spike plasmid, which was generated using funding from the South African Medical Research Council. pCMV-dR8.2 dvpr was a gift from Bob Weinberg (Addgene plasmid # 8455; <http://n2t.net/addgene:8455>; RRID:Addgene_8455). pBOBI-FLuc was a gift from David Nemazee (Addgene plasmid # 170674; <http://n2t.net/addgene:170674>; RRID:Addgene_170674). We acknowledge all staff at the Department of Clinical Microbiology, Karolinska University Hospital involved in SARS-CoV-2 routine diagnostics, S-gene screening and sequencing.

The following reagents were obtained through NIAID, NIH:

Pooled Human Serum Sample, Pfizer Vaccine (BEI Resources: NRH-17727)

Pooled Human Serum Sample, Moderna Vaccine (BEI Resources: NRH-17846)

Pooled Human Serum Sample, Johnson&Johnson Vaccine (details unavailable at the time of submission).

This project was supported, in part, by funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 101003653 (CoroNAb) to G.B.K.H., S.R., and B.M; from the SciLifeLab Call 4.1: Laboratory preparedness for pandemics (Reg no. VC-2021-0033) to B.M. and J.A.; from the Erling Persson Foundation to B.M and G.B.K.H.

Author Contributions

Conceptualization, D.J.S., D.M., G.B.K.H., J.A., B.M.; Formal analysis, D.J.S., B.M.; Investigation, D.J.S., C.K., X.C.D.; Methodology, A.P., D.J.S., B.M.; Visualization, D.J.S., B.M.; Resources, R.E., S.R., J.D., G.B.K.H., J.A.; Supervision, D.J.S., G.B.K.H., S.R., J.A., B.M.; Writing – original draft, D.J.S. and B.M.; Writing – review & editing, D.J.S., D.M., G.B.K.H., J.A., B.M.

Methods

Ethics statement

HW and Convalescent cohorts: Informed consent was obtained from all participants as part of an ethics approval (Decision number 2020-01620, with amendments 2020-02881 and 2020-05630) from the Swedish Ethical Review Authority. BD cohort and the Omicron-positive sample from which the spike was cloned were anonymized, and not subject to ethical approvals, as per advisory statement 2020–01807 from the Swedish Ethical Review Authority.

Donor sample description

Two cohorts were studied. Cohort 1 comprised serum samples with detectable neutralization against the Wu-Hu-1 founder variant from 17 anonymized blood donors (“BD”), donated during week 48, 2021, in Stockholm, Sweden. Cohort 2 comprised 17 serum samples from Hospital Workers (“HW”) at the Karolinska University Hospital in Stockholm²⁰, who were invited to participate in a study that aimed to characterize their antibody responses following SARS-CoV-2 infection and subsequent vaccinations. Participants, confirmed PCR positive, had serum sampled in April/May 2020, in June/July 2020 (“convalescent”, prior to vaccination), and again in November 2021 (“HW”). Convalescent samples are from 9 unique donors, with 3 donors sampled in both April/May 2020 and June/July 2020. Statistical comparison was performed on the 9 samples from June/July 2020 only, to avoid non-independence due to repeated sampling of 3 donors.

Spike expression plasmids

Spike plasmids encoding the B.1, B.1.621, and B.1.617.2 were kindly provided by the G2P-UK National Virology consortium funded by MRC/UKRI (grant ref: MR/W005611/1.) and the Barclay Lab at Imperial College.

An Omicron variant spike was molecularly cloned from an anonymized diagnostic sample, suspected to contain B.1.1.529 due to S-gene target failure and subsequently confirmed by sequencing. A region of spike (with codons corresponding to amino acid positions 43 to 1000) incorporating all of the Omicron variant reference mutations was amplified from cDNA derived from a later-confirmed B.1.1.529 clinical sample obtained from a set of anonymized early cases of suspected Omicron infections. A first PCR round amplified the entire spike gene, and then Gibson assembly overhangs were introduced with a second-round PCR, exploiting regions of existing homology between the codon-optimized parent plasmid and the codon-native spike, in order to maximize overhang length while still keeping primer length under 35bp, allowing for

[illegible]

Cell culture

HEK293T cells (ATCC CRL-3216) and HEK293T-ACE2 cells (stably expressing human ACE2) were cultured in Dulbecco's Modified Eagle Medium (high glucose, with sodium pyruvate) supplemented with 10% fetal calf serum, 100 units/ml Penicillin, and 100 µg/ml Streptomycin. Cultures were maintained in a humidified 37°C incubator (5% CO₂).

Pseudovirus Neutralization Assay

Pseudovirus neutralization assay was performed as previously²². Spike-pseudotyped lentivirus particles were generated by the co-transfection of HEK293T cells with a relevant spike plasmid, an HIV gag-pol packaging plasmid (Addgene #8455), and a lentiviral transfer plasmid encoding firefly luciferase (Addgene #170674) using polyethylenimine (PEI).

Neutralization was assessed in HEK293T-ACE2 cells. Briefly pseudoviruses sufficient to produce ±30,000 RLU were incubated with serial 3-fold dilutions of serum for 60 minutes at 37°C in a black-walled 96-well plate. 10,000 HEK293T-ACE2 cells were then added to each well, and plates were incubated for 48 hours. Luminescence was measured using Bright-Glo (Promega) on a GloMax Navigator Luminometer (Promega). Neutralization was calculated relative to the average of 8 control wells infected in the absence of serum. All fold-change comparisons used ID₅₀ values from neutralization assays run side-by-side.

Monoclonal antibody production:

Antibody sequences were extracted from deposited RCSB entries and codon optimized (using a human germline-aware codon optimization strategy), then synthesized as gene fragments and cloned into pTWIST transient expression vectors by Gibson assembly or restriction cloning (NotI, BamHI). Cloned plasmids were verified by sanger sequencing.

Expi293 cells were transfected with plasmids encoding for the heavy and light chain at 1µg/mL (i.e. 0.5µg/mL each) according to the manufacturer's instructions (ThermoFisher, manual for Cat#A14525). Dense Expi293 cultures (day 5-7 post transfection) were centrifuged at 300xg for 5 minutes to pellet the cells. Supernatant was filtered using Steriflip® 0.22 µm (Merck, SCGP00525) filter units. Expi supernatant was directly loaded onto Protein G Agarose (Pierce, Cat# 20399) gravity columns, washed twice with PBS and eluted using Protein G Elution Buffer (Pierce, Cat# 21004). The eluted fractions were immediately neutralized with 1M TRIS-Buffer (pH = 8) to physiological pH. Absorption at 280 nm was quantified by Nanodrop™ 2000c to determine protein containing fractions. These fractions were then pooled and buffer exchanged using SnakeSkin™ dialysis tubing (10 MWCO, Pierce Cat#68100) followed by further dialysis and concentration using Amicon Ultra-4 10kDa centrifugal units (Merck, Cat# UFC801096). The clinically relevant mAbs tested here were in-house produced versions of: REGN-10933⁶, REGN-10987⁶, LY-CoV555⁷, LY-CoV016⁸, and S309⁹ (from which Sotrovimab was derived through Fc modifications).

Statistical analysis: Individual ID₅₀ values for each sample against each variant were calculated in Prism v9 (GraphPad Software) by fitting a four-parameter logistic curve, to neutralization by serial 3-fold dilutions of serum. Comparisons of titers across variants used

non-parametric Wilcoxon matched-pairs tests. P values are summarized as: ns $P > 0.05$; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$.

References

- 1 Greaney AJ, Loes AN, Crawford KHD, *et al.* Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. *Cell Host Microbe* 2021; **29**: 463–76.e6.
- 2 Cele S, Jackson L, Khan K, *et al.* SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. 2021; published online Dec 9. DOI:10.1101/2021.12.08.21267417.
- 3 Levin EG, Lustig Y, Cohen C, *et al.* Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. *N Engl J Med* 2021; **385**: e84.
- 4 Goldberg Y, Mandel M, Bar-On YM, *et al.* Waning Immunity after the BNT162b2 Vaccine in Israel. *N Engl J Med* 2021; **385**: e85.
- 5 Seow J, Graham C, Merrick B, *et al.* Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nat Microbiol* 2020; **5**: 1598–607.
- 6 Hansen J, Baum A, Pascal KE, *et al.* Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. *Science* 2020; **369**: 1010–4.
- 7 Jones BE, Brown-Augsburger PL, Corbett KS, *et al.* The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. *Sci Transl Med* 2021; **13**. DOI:10.1126/scitranslmed.abf1906.
- 8 Wu X, Li N, Wang G, *et al.* Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study. *Antimicrob Agents Chemother* 2021; **65**: e0035021.
- 9 Pinto D, Park Y-J, Beltramello M, *et al.* Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature* 2020; **583**: 290–5.
- 10 Weinreich DM, Sivapalasingam S, Norton T, *et al.* REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. *N Engl J Med* 2021; **385**: e81.
- 11 Khoury DS, Cromer D, Reynaldi A, *et al.* Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* 2021; **27**: 1205–11.
- 12 Corbett KS, Nason MC, Flach B, *et al.* Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. *Science* 2021; **373**: eabj0299.
- 13 Briefing T. SARS-CoV-2 variants of concern and variants under investigation in England. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1042046/Technical_Briefing_32.pdf.

- 14 Kuhlmann C, Mayer CK, Claassen M, *et al.* Breakthrough Infections with SARS-CoV-2 Omicron Variant Despite Booster Dose of mRNA Vaccine. 2021; published online Dec 9. DOI:10.2139/ssrn.3981711.
- 15 Klevebro S, Bahram F, Elfström KM, *et al.* Risk of SARS-CoV-2 exposure among hospital healthcare workers in relation to patient contact and type of care. *Scand J Public Health* 2021; **49**: 707–12.
- 16 Wang Z, Muecksch F, Schaefer-Babajew D, *et al.* Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. *Nature* 2021; **595**: 426–31.
- 17 Choi A, Koch M, Wu K, *et al.* Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. *Nat Med* 2021; **27**: 2025–31.
- 18 Muecksch F, Weisblum Y, Barnes CO, *et al.* Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. *Immunity* 2021; **54**: 1853–68.e7.
- 19 Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of Concern. [https://www.who.int/news/item/26-11-2021-classification-of-omicron-\(b.1.1.529\)-sars-cov-2-variant-of-concern](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern) (accessed Dec 18, 2021).
- 20 Elfström KM, Blomqvist J, Nilsson P, *et al.* Differences in risk for SARS-CoV-2 infection among healthcare workers. *Prev Med Rep* 2021; **24**: 101518.
- 21 Freed N, Silander O. SARS-CoV2 genome sequencing protocol (1200bp amplicon ‘midnight’ primer set, using Nanopore Rapid kit). 2021; published online July 29. <https://www.protocols.io/view/sars-cov2-genome-sequencing-protocol-1200bp-amplic-bwyp-pfvn> (accessed Dec 9, 2021).
- 22 Sheward DJ, Mandolesi M, Urgard E, Kim C. Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models. *Cell Rep* 2021. <https://www.sciencedirect.com/science/article/pii/S2666379121003189>.

Supplementary Information

Supplementary Figure 1. Neutralization curves for each serum from the HW and BD cohorts against WT (grey) and Omicron/B.1.1.529 (black).

Supplementary Figure 2. Neutralizing activity of sera from blood donors (BD) (squares) and Hospital Workers (HW) (circles) against WT, Delta, and Omicron.

Supplementary Figure 3. Neutralizing activity of sera from a subset of BD (squares) and HW (circles) against B.1, Beta, Mu, and Omicron, from an independent assay replicate. Sample selection was biased towards samples that showed extreme maintenance or loss against Omicron. For the subset of samples included in both runs, Omicron titers were reproducible ($\rho = 0.96$, calculated from IC₅₀s in the log domain).

Supplementary Figure 4. For the subset of samples run against D614G, Omicron, Beta, and Mu, the fold-loss against Omicron (defined as D614G IC50/Omicron IC50) was more strongly correlated with fold-loss against Beta ($\rho = 0.78$, log domain) than Mu ($\rho = 0.57$, log domain).

Supplementary Table 1. List of mutations relative to Wu-Hu-1 in the Omicron spike evaluated here:

A67V
H69-
V70-
T95I
G142D
V143-
Y144-
Y145-
N211-
L212I
+214EPE
G339D
S371L
S373P
S375F
K417N
N440K
G446S
S477N
T478K
E484A
Q493R
G496S
Q498R
N501Y
Y505H
T547K
D614G
H655Y
N679K
P681H
N764K
D796Y
N856K
Q954H
N969K
L981F

Supplementary Table 2. Self-reported vaccination histories of Hospital Workers subsequent to previous infection in early 2020.

ID	Founder IC50	Omicron IC50	Fold reduction	Self reported vaccine history ^a
A	839.9	42.84	19.61	Unknown
B	442.1	213	2.08	AZ, Pfizer (4m)
C	686.3	734.4	0.93	Pfizer, Pfizer (4m)
D	184.8	78.71	2.35	Pfizer, Pfizer (8m)
E	879.3	214.1	4.11	AZ, AZ (5m)
F	230.1	10	23.01	Unknown
G	136.6	16.69	8.18	AZ, Pfizer (4m)
H	259.4	36.39	7.13	Pfizer, Pfizer (8m)
I	439.5	179.1	2.45	AZ, AZ (4m)
J	2202	549.3	4.01	Unknown
K	381.8	207.1	1.84	AZ, AZ (5m)
L	451	155.2	2.91	Pfizer , Pfizer, (5m)
M	338.2	35.85	9.43	Unknown
N	269	15.62	17.22	Pfizer, Pfizer (8m)
O	3748	4053	0.92	Pfizer, Pfizer (2m)
P	291.4	21.81	13.36	Pfizer, Pfizer (4m)
Q	1166	492.7	2.37	Unknown

^aCalendar months between most recent immunization and HW serum sampling day shown in brackets.